Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283621 · ClinicalTrials.gov registry record · NA
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT00283621: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00283621 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283621, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.
Interventions
- DRUG Ifosfamide
- DRUG Adriamycin
- DRUG Aranesp (darbepoetin alfa)
- DRUG Neulasta (pegfilgrastim)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2003-06-02 |
| Est. Completion | 2006-04-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283621
The ClinicalTrials.gov registry entry for NCT00283621 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ifosfamide is the first listed.
NCT00283621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283621 about?
NCT00283621 is a clinical study titled "Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide". To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.
What is the current status of trial NCT00283621?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2003-06-02. Estimated completion is 2006-04-12.
What interventions are being tested in trial NCT00283621?
The interventions under investigation include: Ifosfamide (DRUG), Adriamycin (DRUG), Aranesp (darbepoetin alfa) (DRUG), Neulasta (pegfilgrastim) (DRUG).
Who is sponsoring clinical trial NCT00283621?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.